文献速递乳腺癌

大体积可手术或局部晚期乳腺癌患者新辅助化疗后局部区域复发的预测因素:EORTC 10994/BIG 1-00研究分析

Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study.
PubMed 文献 · Eur J Cancer · 2017-05-18

该III期试验分析1553例接受新辅助化疗后手术±放疗的大体积可手术或局部晚期乳腺癌患者,中位随访4.4年,5年局部区域复发累积发生率为4.9%(95%CI 3.76-6.04)。多因素分析显示乳腺癌亚型是局部区域复发的显著预测因素(p<0.0001),三阴性、HER2阳性未用曲妥珠单抗及HER2阳性用曲妥珠单抗患者较luminal A患者的风险比分别为6.44、6.26和3.37;在≥4枚病理阳性淋巴结患者中,缺乏病理学缓解亦与更高的局部区域复发风险相关(HR 2.43)。

要点

  • 乳腺癌亚型是局部区域复发的显著预测因素,p<0.0001。
  • 三阴性患者较luminal A的局部区域复发HR为6.44(95%CI 2.83-14.69)。
  • ≥4枚病理阳性淋巴结且无病理学缓解者局部区域复发HR为2.43(95%CI 1.34-4.40)。

核心结论

  • 乳腺癌亚型和缺乏病理学缓解是新辅助化疗后局部区域复发的预测因素。

研究设计与样本

  • III期试验(欧洲癌症研究与治疗组织10994),患者接受新辅助化疗后手术,伴或不伴放疗。
  • 放疗按预先规定的指南实施,激素受体阳性者接受辅助内分泌治疗,部分HER2阳性者接受辅助曲妥珠单抗。
  • 采用多因素分析,以局部区域复发为首次事件的时间为主要终点,共纳入1553例合格患者。

主要发现

  • 中位随访4.4年,共76例局部区域复发,5年累积发生率为4.9%(95%CI 3.76-6.04)。
  • 多因素分析中乳腺癌亚型是局部区域复发的显著预测因素(p<0.0001)。
  • 与luminal A患者相比,三阴性患者HR 6.44(95%CI 2.83-14.69),HER2阳性未用曲妥珠单抗者HR 6.26(95%CI 2.81-13.93),HER2阳性用曲妥珠单抗者HR 3.37(95%CI 1.10-10.34)。
  • 在≥4枚病理阳性淋巴结患者中,缺乏病理学缓解与显著更高的局部区域复发风险相关,HR 2.43(95%CI 1.34-4.40,p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Identification of clinicopathological factors predicting for a locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC) could help to decide on the optimal locoregional radiotherapy. The objective of this trial is to identify those factors in the context of a phase III trial (European Organisation for Research and Treatment of Cancer 10994). METHODS: Patients received NAC followed by surgery with or without radiotherapy. Radiotherapy was administered according to pre-specified guidelines. Patients with hormone receptor positive tumours received adjuvant hormonal therapy. A proportion of patients with human epidermal growth factor receptor 2 (HER2) positive cancer received adjuvant trastuzumab. The predictive factors for LRR were identified by multivariate analysis with time to LRR as first event as the primary end-point. RESULTS: The median follow-up was 4.4 years. In 1553 eligible patients, there were 76 LRRs with a 5-year cumulative incidence of 4.9% (95% confidence interval, CI [3.76-6.04]). In multivariate analysis, breast cancer subtype was a significant predictor of LRR (p < 0.0001): hazard ratio (HR) 6.44 (95% CI [2.83-14.69]) for triple negative, 6.26 (95% CI [2.81-13.93]) for HER2+ without trastuzumab (T) and 3.37 (95% CI [1.10-10.34]) for HER2+ with T cancers, all compared to luminal A patients. Lack of pathological response was also associated with significantly higher LRR risk in case of ≥4 pathologically positive nodes, HR 2.43 (95% CI [1.34-4.40], p < 0.0001). CONCLUSION: Breast cancer subtype and lack of pathological response are predictive factors for high LRR after NAC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gillon P, Touati N, Breton-Callu C, et al. Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. Eur J Cancer. 2017. PMID: 28527420. doi:10.1016/j.ejca.2017.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。